Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
5-(2-Fluoro-3-Methoxyphenyl)-1-[[2-Fluoro-6-(Trifluoromethyl)Phenyl]Methyl]-6-Methyl-2,4(1H,3H)-Pyrimidinedione stands out as a complex organic compound with a mouthful of a name but distinct chemical structure. This raw material serves critical roles in the pharmaceutical world, often forming a base for the synthesis of advanced drug molecules or acting as a reference standard in pharma labs. The structure features a combination of fluorinated aromatic rings, methoxy functionality, a methyl group, and a pyrimidinedione core, each contributing unique properties in terms of reactivity, solubility, and interaction with other materials. The compound’s molecular formula, C20H13F5N2O3, underlines its relatively high molecular weight and extensive fluorine content. My personal experience with similar fluorinated compounds has shown that they often lend both metabolic stability and bioactivity, which modern pharmaceutical chemistry values highly.
The appearance of this compound typically presents as a solid, crystalline substance that can manifest as flakes, powder, or occasionally fine crystalline pearls. In the laboratory, clarity on its physical state helps prevent confusion during handling and storage. The density sits in the range of 1.5 g/cm³, a value that matches up with its bulky fluorinated structure. This density, along with its low solubility in water and moderate solubility in organics, drives how formulation teams approach it in development. With a melting point often observed above 160°C, the compound resists decomposition at lower temperatures, providing stability in both storage and chemical transformations common in synthesis labs. In my own workflows, high-melting solids like this call for careful control of heating protocols and equipment calibration, since overheating can trigger hazardous decomposition, especially if fluorine-bearing fragments are released.
The chemical backbone of 5-(2-Fluoro-3-Methoxyphenyl)-1-[[2-Fluoro-6-(Trifluoromethyl)Phenyl]Methyl]-6-Methyl-2,4(1H,3H)-Pyrimidinedione is not only structurally rich but also functionally diverse. The central pyrimidinedione ring connects to two aromatic systems through different linkers—one featuring a trifluoromethyl-substituted phenyl and the other a methoxy-fluorophenyl segment. This kind of complexity enables selective chemical modifications, a fact appreciated by medicinal chemists searching for new leads. The presence of multiple electron-withdrawing fluorines and a stable methoxy function provide resistance against metabolic degradation, often a stumbling block for less-engineered molecules. This structure, built for high specificity and low metabolic liability, aligns with modern synthetic trends where precision trumps brute-force discovery efforts.
The pharma-grade specification of this compound demands purity exceeding 98%, as verified by chromatographic and spectroscopic techniques—chiefly HPLC, NMR, FTIR, and LC-MS. The specification sheet lays out precise values for residual solvents, heavy metals, and single impurity thresholds in line with BP, EP, and USP standards. Any deviation can send a whole batch into re-evaluation or outright rejection, so lab teams hop from test to test, confirming identity, potency, and safety. Handling such material means dealing with batch-to-batch variation, requiring robust quality checks. Based on my experience in pharma QA, failing to meet these parameters can jeopardize compliance, leading to regulatory intervention and manufacturing stoppages. That risk pushes many labs to double-verify with orthogonal methods and to keep detailed records for every kilo shipped or received.
Internationally, the HS Code for this compound lands under 293359, a heading which covers nitrogen heterocyclic compounds. This code links into customs and trade processes, influencing paperwork, tariffs, and compliance requirements around the world. It may sound dry, but any slip-up on HS classification can cause regulatory headaches or shipment delays—a lesson I learned after paperwork setbacks stalled a supply chain for weeks. Getting the code right pays dividends not just for compliance, but for smooth global operation and transparent regulatory reporting, particularly where chemicals have dual-use or controlled substance status.
Working with high-fluorine organic compounds pushes safety to the front. This compound, like many raw materials in pharma, can present risk in high doses or through improper handling. The safety data sheet usually warns of irritation to eyes and skin, respiratory concerns if dust becomes airborne, and potential chronic effects if mishandled over an extended period. Its chemical reactivity, particularly with strong acids or bases, compels teams to set up safe storage practices—fridge or room temperature, away from direct light and moisture, preferably in a well-sealed amber bottle. My safety protocols often mean wearing double gloves, splash goggles, and conducting initial workups behind a fume hood, as those fluorinated moieties can break down into hazardous byproducts under stress or heat. Training staff to recognize and react quickly to chemical spills or exposure makes the difference between a minor incident and a lab-wide shutdown.
As a raw material, 5-(2-Fluoro-3-Methoxyphenyl)-1-[[2-Fluoro-6-(Trifluoromethyl)Phenyl]Methyl]-6-Methyl-2,4(1H,3H)-Pyrimidinedione appeals to medicinal and process chemists who value stable, tunable building blocks in drug synthesis. Its fluorine-rich design is especially sought-after as this often translates to better performance against metabolic enzymes—one of the persistent roadblocks in drug development. Every synthetic chemist I’ve worked alongside wants reliable access to such well-characterized intermediates to cut down unwanted side products and boost final purity. The ability to start syntheses with a compound that offers tunable solid-state and solution properties means fewer stumbles in late-stage scale-up. Smooth access to these raw materials, documented with clear batch records, impurity reports, and transport documentation, creates a predictable workflow all the way through to drug substance production. At every stage, comprehensive traceability and batch-level data guard against counterfeiting, adulteration, and hidden risks—issues that have huge consequences for patient safety far down the line.
While the raw material may not make headlines, its role—and the discipline required to manage it—deserve recognition. Continuous safety training, deep-dive analytical testing, and open collaboration between chemists, supply chain managers, and regulatory teams can manage the risks and assure product quality. Establishing sustainable sourcing, recycling solvent streams, and responsibly handling waste byproducts all make sense for long-term viability, addressing not only the regulatory outlook but also the environmental and human impact of advanced chemistry. In all, a molecule like this tells a story about the hidden backbone of modern medicine: intricate, demanding, and quietly essential for advancing human health.
Chengguan District, Lanzhou, Gansu, China
